Arena Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences:

• Cantor Global Healthcare Conference ? Presenting on Tuesday, October 2, at 1:40 p.m. EDT in New York City
• Leerink Partners Roundtable Series ? Rare Disease & Oncology ? Presenting on Tuesday, October 2, at 2:00 p.m. EDT in New York City

A live audio webcast of the presentations will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentations will be available for 30 days following the events.

About Arena Pharmaceuticals
Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. The most advanced investigational clinical programs are ralinepag (APD811), in a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), expected to commence a Phase 3 program for ulcerative colitis (UC) and a program in Crohn's disease (CD), and which has potential utility for a broad range of immune and inflammatory conditions. Arena is also evaluating olorinab (APD371) in a Phase 2 study for the treatment of visceral pain associated with Crohn's disease, as well as other drug candidates in earlier research and development stages.

In addition, Arena has several collaborations including Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target ? preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ^® - marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "will," "focused on," "potentially," "expected," "potential," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the upcoming presentations and Arena's focus, goals, strategy, clinical programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include that clinical programs may not proceed at the time or in the manner expected or at all, as well as those factors disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, which was filed with the SEC on August 7, 2018. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer                                  
[email protected]
858.210.3636

Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646.627.8384

SOURCE Arena Pharmaceuticals, Inc.